Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Restasis in PROSE Devices for Ocular Surface Disease
NCT04735510Phase 3Withdrawn
- Sponsor
- BostonSight
- Start
- May 2021
- Primary completion
- Sep 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cyclosporine ophthalmic solution in ocular surface disease (OSD), sponsored by BostonSight. Planned start May 2021; status: withdrawn.
02
Drugs
cyclosporine ophthalmic solution
03
Conditions
ocular surface disease (OSD)
Beyond the preview
Go deeper on NCT04735510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04735510.